Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.
about
Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.Tumor heterogenicity: multiple needle biopsies from different lesion sites-key to successful targeted therapy and immunotherapy.
P2860
Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.
@en
type
label
Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.
@en
prefLabel
Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.
@en
P2093
P2860
P1476
Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment
@en
P2093
Aggeliki Rapti
Anastasios Kallianos
Dimitrios Drougas
Dimitrios Paliouras
Evaggelia Athanasiou
Georgia Trakada
Haidong Huang
Lemonia Veletza
Nikolaos Barbetakis
P2860
P304
P356
10.1016/J.RMCR.2017.08.017
P577
2017-08-29T00:00:00Z